CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Technical Advancements in Proteomics Streamline High-throughput Workflows

Over the last two decades, significant advances in technology and new methodologies have made proteomics an extremely powerful tool for protein scientists, biologists and clinical researchers. Scientific discoveries in proteomics largely depend on data analysis and data generation. Mass spectrometry (MS)-based proteomics has expanded significantly with improvements in software, data acquisition, and algorithms to provide more accessible and accurate data.

Direct protein analysis from tissue or biofluids, however, raises a variety of analytical challenges. Protein expression varies depending on the genetic background of an individual, and also on time, localisation, and as a physiological response to external stimuli. Moreover, because of the combined effects of alternative splicing, point mutation, post-translational modifications (PTMs) and endogenous proteolysis, a given protein can be expressed as many different proteoforms, each having a dedicated biological activity.

These analytical challenges create workflow bottlenecks and extend the time required for accurate results. This article will examine how these issues can be overcome to add efficiencies and expand capabilities for library-based approaches in quantitative proteomics.

Challenges in Proteomics

The core challenges in proteomics include converting complex liquid chromatography (LC) coupled with MS and the resulting datasets into tangible peptide spectrum matches (PSMs) and peptide identifications that can be used for protein inference, quantification, posttranslational modification (PTM) analysis, as well as proteome sequence coverage within complex samples. Database search algorithms have extensively transformed biological and medical research, yet as analytical instrumentation continues to become more sensitive, software developers must continuously expand these search algorithms to meet the demands of sample limitations in high-throughput protein quantitation.

In the simplest scenario, database search algorithms rely on precursor and fragment ion spectra to be matched in silico, suggesting the best fit and assigning a probability score. In many instances the best fit of a particular PSM is of an equal probability score or just marginally better than the next best fit, yet a single assignment is delivered. Inferring only one PSM, which may be incorrect given the reliance purely on the information contained in a fragment ion spectra, can lead to a greater chance of false identifications. As such, the field of proteomics benefits from stricter acceptance criteria such as lower false discovery rates, increases in unique peptide counts, protein sequence coverage and biological or technical replicates.

Advances in Database Search Platforms

To break the data analysis bottleneck, proteomics software developers are integrating real-time database search and smart acquisition in software algorithms. A parallel search engine in real-time (PaSER) is a GPU-powered real-time database search platform providing parallel computing power and real-time database search results for bottom-up proteomics. Researchers can view intricate details of data from the high-level experimental information to a specific fragment ion spectrum of interest. Additionally, a user-defined qualification of proteins or peptides at the end of a sample acquisition determines the progression of the sample queue, which checks suitability while also making the most of samples, consumables and instrument time.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026